CTLA4 anticorps (FITC)

N° du produit ABIN161253

Détail du produit anti-CTLA4 anticorps (FITC)

Antigène: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Reactivité: Rat

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CTLA4 est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Specificité: Rat CD152

Immunogène: Purified rCTLA-4hlg fusion protein . Fusion Partner: X63 Ag8.653 myeloma cells . Donor: BALB/c mice spleen cells

Clone: WKH 203

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Concentration: 0.1 mg/ml

Buffer: FITC conjugated Ig buffered in PBS, 0.02% NaN and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. (Purified from ascitic fluid via Protein G Chromatography).

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Détails sur CTLA4

Antigène: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Autre désignation: CD152 (CTLA-4) (CTLA4 Produits)

Synonymes: anticorps CTLA-4, anticorps CTLA4, anticorps CD152, anticorps Cd152, anticorps Ctla-4, anticorps Ly-56, anticorps CD, anticorps CELIAC3, anticorps GRD4, anticorps GSE, anticorps IDDM12, anticorps sCTLA4, anticorps cytotoxic T-lymphocyte associated protein 4, anticorps cytotoxic T-lymphocyte-associated protein 4, anticorps CTLA4, anticorps Ctla4

Sujet: Anti-rat CD152 monoclonal antibody is specific for the cytotoxic T lymphocyte- associated protein 4 (CTLA-4), also called CD152. This antigen is known to be the receptor for B7 ligands (CD80 and CD86) present on antigen presenting cells. A subset of CD4 T cells expressing CD25 and CTLA-4 has been recognized as a potent suppressor cell popu- lation, counteracting autoimmunity and inflammation. These `regulatory' T cells (Treg) which produce the anti-inflammatory cytokine interleukin-10 (IL-10) but not IL-2, are able to suppress the proliferation of costimulated CD25- negative indicator cells. The capacity of these naturally occurring regulatory T cells to suppress autoimmunity and inflammation suggests that therapies which activate and expand this subset could become extremely effective treatments for these immunopathological disorders. This clone has been tested in flow cytometry. In rats, the constitutive expression of CTLA-4 at the level detectable by flow cytometry is restricted to the CD25+ subset of CD4 T cells and thymocytes.

Pathways: Cancer Immune Checkpoints